Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
Jazz Pharmaceuticals announced the publication of Phase 3 HERIZON-GEA-01 trial results in The New England Journal of Medicine, confirming durable survival benefits for Ziihera (zanidatamab-hrii) in first-line HER2+ gastroesophageal adenocarcinoma. The data showed superior progression-free survival (12.4 vs 8.1 months) and overall survival (26.4 vs 19.2 months) for zanidatamab plus tislelizumab and chemotherapy compared to trastuzumab plus chemotherapy, with a hazard ratio of 0.72 for OS.
Key figures
- Drug Name
- Ziihera (zanidatamab-hrii)
- Phase Of Trial
- Phase 3
- Trial patients
- 914
- Os hazard ratio
- 0.72
- Pfs hazard ratio
- 0.63-0.65
- Median os trastuzumab
- 19.2 months
- Median pfs trastuzumab
- 8.1 months
- Median pfs zanidatamab
- 12.4 months
- Median os pd l1 negative
- 29.7 months
- Median os pd l1 negative control
- 15.8 months
- Median os zanidatamab tislelizumab
- 26.4 months
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.